The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

NC State researchers found that blueberry powdery mildew has spread globally in two strains, costing the industry up to $530 ...

Development Team Team Novo Nordisk partner with Selle San Marco for 2025 season Benidorm wants the cyclocross World ...

Instead, it allowed for a blood sample to be inoculated with a radioactive form of thyroid hormone. Ausria, a radioimmunoassay test to detect serum hepatitis, was launched in 1972 and marked the ...